College Confers Medical Degrees on 50 More Physicians in Addressing Doctor ShortageContinue reading
Author Archive: AZBio
Ivy Interns: The next generation of researchers to study the brain
Ivy Foundation Renews Support for TGen Neurological Sciences Internship Program. Second year of training opportunities focused on brain tumors and neuroscienceContinue reading
UA Geneticists Find Causes for Severe Childhood Epilepsies
Using a state-of-the-art DNA sequencing technique, UA researchers have discovered genetic mutations underlying seizure disorders in previously undiagnosed childrenContinue reading
UA Research Suggests Link Between Elevated Blood Sugar, Alzheimer’s Risk
About 5 percent of men and women, ages 65 to 74, have Alzheimer’s disease, and it is estimated that nearly half of those age 85 and older may have the disease. Among known risks are age and geneticsContinue reading
Calimmune an example of Bioscience That Will Blow your Mind
Milken Institute Video from the Global Conference 2013 highlights thought leaders, breakthroughs, and what needs to come next.Continue reading
Congressman Gosar shares thoughts on IPAB at Medicare Today TeleTown Hall
On April 23rd, organizations from across the U.S. participated in a national tele-town hall with Representatives Matheson (D-UT) and Gosar (R-AZ) on the importance of IPAB repeal. A recording of the tele-town hall can replayed here. (Audio) Continue reading
2013 EY Beyond Borders Report for the Life Science Industry
The business climate for the biotechnology industry remains challenging. In today’s “new normal,” venture capitalists are more selective, IPOs more elusive and alliance partners more demanding. And even as biotech companies grapple with these challenges, health care systems are undergoing a fundamental shift toward outcomes and pay-for-performance.
How is the industry dealing with the twin challenges of boosting operating efficiency and demonstrating economic value?
Are “HOLNets” gaining traction and making R&D more efficient?
What are companies doing differently to collect data and demonstrate the economic value of their products?
Ernst & Young’s Beyond Borders offers insights on these questions and more.
Want to learn more?
Contact Phil Howard and the E&Y Life Sciences Team
in Phoenix at (602) 322-3000.
BIOTECH INVESTING Milestones in Drug Development
Info graphic highlights the key steps for investors to watch in the drug development process. Continue reading
US OMB Proposes Updating Grant Guidance for Federal Programs
The US Office of Management and Budget has proposed streamlining its grant guidance and making other changes aimed at increasing the effectiveness and efficiency of federal programs. Continue reading
Sanofi expands global leadership team
Sanofi appoints two new Members to the Executive Committee to lead the new Commercial OrganizationContinue reading